You are here

Optimized Platforms for Proper Glycosylation and Sialylation of Recombinant Human Butyrylcholinesterase (rBChE)

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911SR-21-C-5000
Agency Tracking Number: C2-0587
Amount: $541,247.16
Phase: Phase II
Program: SBIR
Solicitation Topic Code: CBD192-007
Solicitation Number: 19.2
Timeline
Solicitation Year: 2019
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-15
Award End Date (Contract End Date): 2023-09-15
Small Business Information
1515 West 2200 South Suite F
Salt Lake City, UT 84119-1441
United States
DUNS: 829431076
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: Yes
Principal Investigator
 Robert Price
 (801) 915-7973
 robert@tekholding.com
Business Contact
 Mukund Karanjikar
Phone: (801) 953-1047
Email: mukund@tekholding.com
Research Institution
N/A
Abstract

The threat of organophosphate (OP) chemical warfare agents (CWA) to United States military personnel is a persistent problem due to the relative ease of manufacturing chemical threats compared to nuclear and biological agents. Human butyrylcholinesterase (HuBChE) has been identified as a probable bio-scavenger of OP CWAs that could be used to protect individuals that could be exposed to OP CWAs. The goal of this project is to generate a mammalian cell line capable of expressing human HuBChE in tetrameric form with appropriate human glycosylation patterns . To achieve this goal we will down select among our multiple HuBChE expressing cell lines and humanize the observed glycosylation patterns to match the plasma derived HuBChE standard. This approach will be evaluated to determine technical and economic applicability to full scale manufacturing.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government